PDL BioPharma, Inc. (NASDAQ:PDLI) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders.
On June 8, 2018, the Company held its 2018 Annual Meeting of Stockholders in Incline Village, Nevada. At the annual meeting, the Company’s stockholders: (i) elected each of Jody Lindell, John McLaughlin and Shlomo Yanai to the Company’s Board of Directors for a term of three years, (ii) ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditors for the fiscal year ending December 31, 2018, (iii) approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s proxy statement and (iv) approved the Amended and Restated 2005 Equity Incentive Plan.
Represented in person or by proxy at the annual meeting were 127,760,040 shares of the Company’s common stock, or 85.04% of the total number of shares outstanding as of the record date. The results of the matters submitted to a stockholder vote at the annual meeting were as follows.
1.Election of Directors:
|
Name |
For |
Withheld |
Broker Non-Votes |
|
Jody Lindell |
92,261,744 |
5,588,155 |
29,910,141 |
|
John McLaughlin |
92,175,956 |
5,673,943 |
29,910,141 |
|
Shlomo Yanai |
94,947,323 |
2,902,576 |
29,910,141 |
|
2. |
Ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018: |
|
For |
Against |
Abstain |
|
126,640,987 |
779,154 |
339,899 |
|
3. |
Approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s proxy statement: |
|
For |
Against |
Abstain |
Broker Non-Votes |
|
91,079,972 |
6,451,964 |
317,963 |
29,910,141 |
|
4. |
Approve the Amended and Restated 2005 Equity Incentive Plan of the Company: |
|
For |
Against |
Abstain |
Broker Non-Votes |
|
90,191,887 |
7,321,799 |
336,213 |
29,910,141 |
Item 8.01 Other Events.
On May 11, 2018, the Company issued a press release announcing the election of Shlomo Yanai to the Company’s Board of Directors. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
PDL BIOPHARMA, INC. ExhibitEX-99.1 2 pdli-201806118xkex991.htm PRESS RELEASE Exhibit Exhibit 99.1Shlomo Yanai Elected to PDL BioPharma’s Board of DirectorsINCLINE VILLAGE,…To view the full exhibit click here
About PDL BioPharma, Inc. (NASDAQ:PDLI)
PDL BioPharma, Inc., formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions and inventors. It evaluates its investments based on the quality of the income generating assets and potential returns on investment. It is focused on intellectual property asset management, acquiring income generating assets and maximizing value for its stockholders, among others. It receives royalties on sales of over ten humanized antibody products, which include Avastin, Herceptin, Xolair, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio all of which are approved for use.
